Robert Glanzman

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Ludwig Kappos, David Li, Peter A. Calabresi et al. · The Lancet · 2011 · 741 citations

Life Sciences, Neurology, Pharmacotherapy +8

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Hans-Peter Hartung, Bruce Cree, Maria Pia Sormani et al. · Multiple Sclerosis Journal · 2021 · 81 citations · Full text

Life Sciences, Neurology, Neuroscience +14

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension

Steve Vucic, Parvathi Menon, William Huynh et al. · EClinicalMedicine · 2023 · 61 citations · Full text

Life Sciences, Neurology, Neuroscience +15

Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment

Steve Vucic, Toby A. Ferguson, Catherine Cummings et al. · Muscle & Nerve · 2021 · 55 citations

Life Sciences, Neurology, Neuroscience +17

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

Steve Vucic, Matthew C. Kiernan, Parvathi Menon et al. · BMJ Open · 2021 · 51 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17